AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2020
Jun 2, 2020
62616_rns_2020-06-02_b923f66a-f1ab-4741-8794-f375594df18e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
June 2, 2020
BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR
Dear Madam/ Sir,
Subject: Press Release
Please find attached Press Release issued by the Company titled:
“Strides receives USFDA approval for Triamcinolone Acetonide Ointment”
Thanking you,
Yours faithfully,
For Strides Pharma Science Limited Manjula Ramamurthy Company Secretary Encl. As above
Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 [email protected]; www.strides.com
Press Release June 02, 2020
Strides receives USFDA approval for Triamcinolone Acetonide Ointment
Product approval from flagship facility in Bangalore
To be marketed by Strides Pharma Inc. in the US market
Bangalore, June 02, 2020 ‐ Strides Pharma Science Limited (Strides) today announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 15 Mn. The product will be manufactured at the company’s flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.
The company has 124 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 38 are pending approval.
About Triamcinolone Acetonide Ointment
Triamcinolone Acetonide Ointment 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India‐ Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy‐ Milan, Kenya‐ Nairobi and United States‐Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com
For further information, please contact:
| Strides Badree Komandur Executive Director ‐ Finance +91 80 6784 0747 Investor Relations: Sandeep Baid:+91 80 6784 0791 |
PR Consultancy Fortuna PR K Srinivas Reddy: +91 90005 27213 [email protected] K Priya: +91 95354 25418 [email protected] |
|
|---|---|---|
Kannan. N: +91 98450 54745 Email: [email protected] Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector ‐ 17, Vashi, Navi Mumbai ‐ 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560 076